A new study led by researchers at Karolinska Institutet has shown that specific blood biomarkers could predict the onset of dementia, including Alzheimer's disease, up to ten years before an actual diagnosis in older adults living independently.
In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer.
Researchers have revealed a new finding that could improve cancer care immunotherapy treatments, particularly for chronic lymphocytic leukaemia (CLL) and other cancers.
Thousands of patients in England with multiple sclerosis (MS) are expected to benefit from the new treatment. This comes after the NHS becomes the first healthcare system in Europe to roll out a "take at home" tablet for individuals with active disease.
The UK Health Security Agency (UKHSA) has recently launched a genomic surveillance programme to monitor the hepatitis C virus (HCV) and its response to treatment.
After the NHS announced the launch of their first ever breast cancer screening campaign, tens of thousands of women have been accessing vital advice on attending mammograms.
Professor David Sebag-Montefiore outlines the profound impact of radiotherapy research. Through global trials and personalised approaches, innovation advances cancer care. Collaborative efforts ensure patient-centred treatments, paving the way for smarter, kinder therapies and a future of precision oncology.
Recently, a study that was published in Nature Mental Health showed concerns about the use of acetaminophen during pregnancy and its potential link to the development of attention-deficit/hyperactivity disorder (ADHD) in children.
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS for children and adults living with Lennox–Gastaut syndrome (LGS).
Trevor Graham, Professor of Genomics and Evolution and the Director of the Centre for Evolution and Cancer at the Institute of Cancer Research, London, describes efforts to incorporate genome sequencing for cancer detection and treatment.
We all have a unique face, fingerprint, voice, and signature, so why wouldn’t we have a unique response to the medicine and treatments we receive? Mark Hitchman, Managing Director at Canon Medical Systems UK, explores this question.
